VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

T-cell defects and premature thymic atrophy occur in cancer patients and tumor-bearing animals. We demonstrate that exposure of mice to recombinant vascular endothelial growth factor (VEGF) at concentrations similar to those observed in advanced stage cancer patients reproduces this profound thymic atrophy and is highlighted by a dramatic reduction in CD4+/CD8+ thymocytes. We find that VEGF does not induce thymocyte apoptosis, but instead rapidly decreases the number of the earliest observable progenitors in the thymus. VEGF does not inhibit thymocyte development in fetal thymic organ culture, further suggesting a prethymic effect. We also demonstrate that bone marrow progenitors from animals infused with recombinant VEGF and transferred to irradiated untreated animals recolonize the thymus more efficiently than progenitors from control animals. This suggests that VEGF exposure is associated with an increased population of thymus-committed progenitors in the bone marrow. We hypothesize that pathophysiologically relevant concentrations of VEGF may block the differentiation and/or emigration of these progenitors resulting in the observed thymic atrophy. Removal of VEGF via cessation of infusion or adoptive transfer of progenitors to a congenic host induces a preferential commitment of lymphoid progenitors to the T lineage and results in a restoration of the normal composition and cellularity of the thymus. These data demonstrate that at pathophysiologic concentrations, VEGF interferes with the development of T cells from early hematopoetic progenitor cells and this may contribute to tumor-associated immune deficiencies.

[1]  K. Arai,et al.  Interleukin‐7 inhibits pre‐T‐cell differentiation induced by the pre‐T‐cell receptor signal and the effect is mimicked by hGM‐CSF in hGM‐CSF receptor transgenic mice , 2002, Immunology.

[2]  H. Liao,et al.  T cell receptor excision circle assessment of thymopoiesis in aging mice. , 2002, Molecular immunology.

[3]  I. Goldschneider,et al.  The Importation of Hematogenous Precursors by the Thymus Is a Gated Phenomenon in Normal Adult Mice , 2001, The Journal of experimental medicine.

[4]  I. Weissman,et al.  Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines , 2000, Nature.

[5]  B. Adkins,et al.  Early Block in Maturation Is Associated with Thymic Involution in Mammary Tumor-Bearing Mice1 , 2000, The Journal of Immunology.

[6]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  D. Templeton,et al.  Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. , 1999, Journal of immunology.

[8]  D. Carbone,et al.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  R. Kiessling,et al.  Tumor-induced immune dysfunction , 1999, Cancer Immunology, Immunotherapy.

[10]  C. Peschle,et al.  KDR receptor: a key marker defining hematopoietic stem cells. , 1999, Science.

[11]  J. Finke,et al.  Where have all the T cells gone? Mechanisms of immune evasion by tumors. , 1999, Immunology today.

[12]  G. Pawelec,et al.  T cells and aging (update february 1999). , 1999, Frontiers in bioscience : a journal and virtual library.

[13]  T. Gajewski,et al.  The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. , 1999, Critical reviews in oncogenesis.

[14]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[15]  S. Nishikawa,et al.  Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. , 1998, Development.

[16]  R. Flavell,et al.  Immunologic nonresponsiveness to tumors. , 1998, Critical reviews in oncogenesis.

[17]  W. Savino,et al.  Epidermal Growth Factor Modulates Fetal Thymocyte Growth and Differentiation , 1998, Developmental immunology.

[18]  G. Pawelec,et al.  Escape from host-antitumor immunity. , 1997, Critical reviews in oncogenesis.

[19]  J. Krauss,et al.  Tumor immunology. , 1997, JAMA.

[20]  Andrew W. Murray,et al.  Association of Spindle Assembly Checkpoint Component XMAD2 with Unattached Kinetochores , 1996, Science.

[21]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[22]  D. Carbone,et al.  Immunologic dysfunction in cancer. , 1996, Hematology/oncology clinics of North America.

[23]  Hiromitsu Nakauchi,et al.  Long-Term Lymphohematopoietic Reconstitution by a Single CD34-Low/Negative Hematopoietic Stem Cell , 1996, Science.

[24]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[25]  D. Carbone,et al.  Erratum: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (Nature Medicine 2, 1096-1103 (1996)) , 1996 .

[26]  I. Weissman,et al.  The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. , 1994, Immunity.

[27]  S. Goldman,et al.  Hematology/Oncology Clinics of North America , 2020, Hematology/Oncology Clinics of North America.

[28]  D. Lopez,et al.  Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas. , 1989, Journal of immunology.

[29]  M. Zhang [The relationships between thymus, other immune organs and various diseases in children (analysis of 621 cases)]. , 1989, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[30]  C. Rosse,et al.  Induction of granulocytic hyperplasia, thymic atrophy, and hypercalcemia by a selected subpopulation of a murine mammary adenocarcinoma. , 1985, Cancer research.

[31]  W. Savino,et al.  Studies of the thymus in mice bearing the Lewis lung carcinoma. III. Possible mechanisms of tumor-induced thymic atrophy. , 1984, Clinical immunology and immunopathology.

[32]  C. Rosse,et al.  Depletion of lymphocyte subpopulations in primary and secondary lymphoid organs of mice by a transplanted granulocytosis-inducing mammary carcinoma. , 1982, Cancer research.

[33]  O RAJKA,et al.  [TUMOR IMMUNOLOGY]. , 1963, Orvosi hetilap.